Apitegromab: Community Protocols & Reports
Aggregated community experiences, protocols, and stacking patterns
Community-Sourced Information
The protocols and reports on this page are gathered from online communities and forums. They represent anecdotal experiences, not clinical evidence. Individual results vary significantly. This information is not medical advice and should not replace consultation with a qualified healthcare provider. Always verify dosing and safety information with peer-reviewed research before making any decisions.
For peer-reviewed dosing protocols, see the clinical dosing guide.
Browse community protocols for all 130 peptides →
📌TL;DR
- •2 community protocols documented
- •Evidence level: Anecdotal Reports
- •Based on 20 community reports
- •1 stacking patterns reported
Clinical vs. Community Protocol Differences
How community-reported protocols differ from clinical research protocols.
| Aspect | Clinical Approach | Community Approach | Significance |
|---|---|---|---|
| Clinical Trial Only | Apitegromab is currently in Phase 3 clinical trials for spinal muscular atrophy (SAPPHIRE trial) and Phase 2 for obesity-related lean mass loss (EMBRAZE trial). Administration is by IV infusion in clinical settings. | Community discussion is limited to clinical trial participation and research interest. Apitegromab is not available through research peptide channels due to its nature as a monoclonal antibody requiring sophisticated manufacturing. | high Unlike small peptides, monoclonal antibodies like apitegromab cannot be synthesized outside pharmaceutical manufacturing facilities. Community use outside clinical trials is not feasible. |
Compare these community approaches with published research findings.
Community Protocols
SAPPHIRE Phase 3 Protocol
Niche- Route
- Intravenous infusion
- Dose
- 20 mg/kg
- Frequency
- Every 4 weeks
- Duration
- 52 weeks (trial duration)
Phase 3 clinical trial protocol; not yet commercially available
EMBRAZE Obesity Protocol
Niche- Route
- Intravenous infusion
- Dose
- Dose not yet publicly disclosed in detail
- Frequency
- Every 4 weeks
- Duration
- Phase 2 trial ongoing
Investigational combination with tirzepatide for lean mass preservation during weight loss
Stacking Patterns
Apitegromab + Tirzepatide (EMBRAZE Trial)
NicheInvestigational combination for preserving lean mass during GLP-1 mediated weight loss; EMBRAZE Phase 2 showed 54.9% lean mass preservation
Check stack compatibility and review potential side effects before combining peptides.
Unlock community dosing protocols and stacking combos
See the exact doses, routes, and schedules 20+ self-experimenters report. Free with email.
150+ peptide profiles · 30+ comparisons · 18 research tools
Sources
- Reddit r/SpinalMuscularAtrophy|Apitegromab SAPPHIRE trial results and SMA treatment discussions(accessed 2026-02-16)
- CureSMA|Clinical trial updates and treatment pipeline information(accessed 2026-02-16)
- Reddit r/Peptides|Myostatin inhibitor pipeline discussions including apitegromab(accessed 2026-02-16)
Community Evidence Overview#
This page presents aggregated community discussions and context for apitegromab (SRK-015). This is not clinical evidence and should not be used as medical guidance.
Apitegromab is an investigational monoclonal antibody currently in clinical trials. It is not commercially available and cannot be obtained outside of clinical trial participation. Community discussion is primarily found in SMA patient advocacy groups, clinical trial forums, and among researchers following the myostatin inhibition pipeline.
Current Development Status#
Apitegromab is being developed by Scholar Rock for two primary indications:
- Spinal Muscular Atrophy (SMA): The Phase 3 SAPPHIRE trial met its primary endpoint, showing significant motor function improvement as add-on therapy
- Obesity (lean mass preservation): The Phase 2 EMBRAZE trial is evaluating the combination with tirzepatide
SMA Community Interest#
The SMA community has shown significant interest in apitegromab as a potential complementary therapy to existing SMN-correcting treatments (nusinersen, risdiplam, onasemnogene). Patient advocacy groups such as CureSMA provide updates on clinical trial progress and regulatory milestones.
Bodybuilding and Fitness Community Interest#
Interest from bodybuilding and fitness communities is primarily theoretical, focused on the potential for myostatin inhibition to enhance lean mass. However, apitegromab is a monoclonal antibody administered by IV infusion in clinical settings and is not a practical candidate for non-medical use.
Related Reading#
Subscribe to see vendor options
Free access to verified vendor scores, pricing, and suppliers.
150+ peptide profiles · 30+ comparisons · 18 research tools
Frequently Asked Questions About Apitegromab
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.